Leukoreduction: Process & Purpose

Leukoreduction (also called leukocyte reduction or leukofiltration) is the process of removing most of the white blood cells (leukocytes) from a unit of red blood cells or platelets before or at the time of transfusion, using a specialized filter designed to trap leukocytes while letting red cells or platelets pass through. It is a routine blood-banking processing step, not an experimental technique, and it solves a different problem than irradiation of blood products, with which it is frequently confused.

The purpose of leukoreduction is to reduce the clinical consequences of the residual donor white cells that would otherwise remain in a transfused unit: febrile transfusion reactions, cytomegalovirus (CMV) transmission risk, and the buildup of antibodies against donor white-cell antigens (HLA alloimmunization) in patients who receive repeated transfusions.

What leukoreduction actually removes, and how

A leukoreduction filter is a specialized depth filter, typically made of a tightly packed polyester or similar synthetic fiber medium, sized to physically trap white blood cells by a combination of mechanical straining and adhesion while allowing the much more numerous, smaller red cells or platelets to pass through largely unaffected. A properly performed leukoreduction removes the great majority of leukocytes present in the original unit — typically framed as a three-log (99.9%) or greater reduction — rather than removing them completely.

Leukoreduction is a physical filtration step. It does not alter the white cells that remain, and it does not affect the red cells’ or platelets’ ability to function. This is the key distinction from irradiation, which leaves leukocytes physically present in the unit but disables their ability to proliferate (see the comparison section below).

Why leukoreduction of blood products is performed

Leukoreduction addresses several distinct, well-documented clinical problems caused by donor white cells in a transfused unit:

Febrile non-hemolytic transfusion reactions (FNHTR). Cytokines released by donor white cells — both during storage and in response to the recipient’s immune system after transfusion — are a major cause of fever, chills, and general discomfort during or shortly after transfusion. Reducing the white-cell load reduces the cytokine burden and the frequency of these reactions.
Cytomegalovirus (CMV) transmission risk. CMV is carried inside white blood cells, not in plasma or in mature red cells or platelets themselves. Removing most of the leukocytes substantially lowers the risk of transmitting CMV through transfusion, which is why leukoreduced components are widely used as a risk-reduction strategy for CMV-seronegative patients who are at risk of severe primary CMV infection — low-birthweight neonates, transplant candidates and recipients, and other significantly immunocompromised patients. Leukoreduced components are generally treated as an accepted alternative to CMV-seronegative units for this purpose, though the two are not tested or defined identically, and institutional policy determines which is used or required in a given clinical situation.
HLA alloimmunization. Repeated exposure to donor white cells carrying foreign HLA antigens can cause a recipient to develop antibodies against those antigens. Over time this can lead to platelet transfusion refractoriness (transfused platelets are destroyed before they can work) and can complicate future organ or stem-cell transplant matching. Leukoreduction, particularly when performed before storage, measurably reduces the rate of HLA alloimmunization in chronically transfused patients.
Transfusion-related immunomodulation (TRIM). Donor leukocytes are implicated in broader immune-modulating effects associated with transfusion; leukoreduction is one of the mitigation strategies used to reduce this exposure, alongside other blood-management practices.

Pre-storage vs. bedside leukoreduction

Leukoreduction of blood products can be performed at two different points in the process, and the timing matters clinically, not just operationally:

Pre-storage (in-process) leukoreduction filters the unit shortly after collection, before it goes into refrigerated or room-temperature storage. Because the white cells are removed before they have time to break down and release cytokines into the unit during storage, pre-storage leukoreduction is more effective at preventing febrile reactions than filtering later, and it is the method most blood collection organizations use for routine, universal leukoreduction programs.
Bedside (post-storage) leukoreduction filters the unit at the point of transfusion, using an in-line filter attached to the administration set. It still removes most of the white cells present at that time and provides meaningful HLA-alloimmunization and CMV-risk benefit, but any cytokines that have already accumulated in the unit during storage are not removed, so it is less effective than pre-storage filtration specifically for preventing febrile reactions.

Which blood components are leukoreduced

Leukoreduction applies to the cellular components that carry a clinically significant white-cell burden:

Red blood cell (RBC) units — commonly leukoreduced, either universally or selectively depending on the blood supplier and jurisdiction.
Platelet products (both whole-blood-derived and apheresis platelets) — apheresis platelet collection instruments frequently leukoreduce as part of the collection process itself; whole-blood-derived platelet pools are typically filtered afterward.

Fresh frozen plasma and cryoprecipitate are not leukoreduced, since they are separated from the cellular fraction of the donation and do not carry a significant residual white-cell load in the first place.

Universal vs. selective leukoreduction

Practice differs by country. A number of jurisdictions — including Canada, the United Kingdom, and most of the rest of Europe — adopted universal leukoreduction, filtering essentially all cellular blood components regardless of the individual recipient’s risk profile, in large part as a precautionary measure against variant Creutzfeldt-Jakob disease (vCJD) transmission in addition to the transfusion-reaction and alloimmunization benefits described above. In the United States, leukoreduction is not universally mandated by federal regulation; many blood collection organizations leukoreduce the large majority of their cellular components as standard practice, while some institutions and blood suppliers still leukoreduce selectively based on a specific patient’s clinical indication. A transfusion service’s own policy, not a single nationwide rule, determines whether a given unit arrives already leukoreduced or whether leukoreduction has to be ordered for a specific patient.

Quality standards and validation

Leukoreduction is a validated, quality-controlled process, not an assumed effect of running a unit through a filter. In AABB-accredited transfusion services and blood collection facilities in the United States, a leukoreduced red cell or platelet unit must meet a defined residual white-cell count threshold — commonly referenced as fewer than 5 × 10⁶ residual leukocytes per unit — confirmed through ongoing quality-control sample testing across a defined percentage of leukoreduced units, with the process re-validated whenever equipment or filter lots change. This sits within the same broader accreditation framework transfusion services already operate under for other cellular blood-component modifications, alongside GxP-style quality-system requirements and, where the laboratory itself is CLIA-regulated, its CLIA certification status. Institutions should verify current residual-leukocyte thresholds and QC testing frequency against their accrediting body’s live standards rather than a secondary summary, since the specific numeric threshold and sampling requirements are exactly the kind of operational detail that gets revised between standard editions.

Leukoreduction vs. irradiation: not the same process

Leukoreduction and irradiation are frequently confused because both processes address white blood cells in a transfused unit, but they solve entirely different clinical problems and neither substitutes for the other:

Leukoreduction physically filters most leukocytes out of the unit, primarily to reduce febrile non-hemolytic transfusion reactions, CMV transmission risk, and HLA alloimmunization.
Irradiation leaves the leukocytes physically present but disables their ability to proliferate, specifically to prevent transfusion-associated graft-versus-host disease (TA-GVHD).

Leukoreduction alone does not remove enough viable, proliferation-capable lymphocytes to reliably prevent TA-GVHD in a patient who has a recognized indication for irradiation — a leukoreduced-but-not-irradiated unit still carries meaningful TA-GVHD risk for a susceptible recipient. Conversely, irradiation alone does not address febrile reactions, CMV risk, or alloimmunization, since it leaves the leukocytes in the unit rather than removing them. Many units are both leukoreduced and irradiated when a patient’s clinical situation calls for both, and transfusion services order them as separate, independently documented specifications on a blood product request rather than assuming one implies the other.

What leukoreduction does not do

Leukoreduction is not a sterilization step and does not address bacterial or most viral contamination outside of the specific CMV-risk-reduction role described above; it plays no role in inactivating bacteria introduced during collection or processing, which are addressed through donor screening, skin-disinfection technique at collection, and (for platelets specifically) bacterial detection testing. It is also not a substitute for CMV-seronegative testing when institutional policy or a specific clinical scenario requires seronegative units rather than the leukoreduced alternative, and it is not a substitute for irradiation when TA-GVHD prevention is the clinical need.

Frequently asked questions

What is leukoreduction?

Leukoreduction is the process of filtering most white blood cells out of a red blood cell or platelet unit, either shortly after collection (pre-storage) or at the bedside during transfusion, to reduce febrile transfusion reactions, CMV transmission risk, and HLA alloimmunization from repeated donor white-cell exposure.

What is the difference between leukoreduction and irradiation?

Leukoreduction physically removes most white blood cells from a unit; irradiation leaves white blood cells in the unit but disables their ability to divide. Leukoreduction targets febrile reactions, CMV risk, and alloimmunization; irradiation targets transfusion-associated graft-versus-host disease. They are ordered independently and a patient may need one, both, or neither depending on clinical indication.

Is leukoreduction required for all blood products?

Not in the United States, where leukoreduction is common but not universally mandated by federal regulation; many other countries, including Canada and most of Europe, require universal leukoreduction of cellular blood components. Institutional and supplier policy determines actual practice in a given setting.

Does leukoreduction replace the need for CMV-seronegative blood?

In many institutions, leukoreduced components are accepted as an alternative to CMV-seronegative units for CMV-risk reduction, but the two are not identical, and some clinical scenarios or institutional policies still specify CMV-seronegative units specifically. Check the applicable policy for the patient population in question rather than assuming equivalence.